Rampant Increase in Cases of Mucormycosis in India and Pakistan: A Serious Cause for Concern during the Ongoing COVID-19 Pandemic

Abstract

COVID-19 is a global health crisis that continues to pose new challenges all around the world. Amidst the growing pandemic, a spike in the number of mucormycosis cases in India and Pakistan has been reported in COVID-19 patients and in those who have recovered from COVID-19. This increase in cases may be related to the overuse of steroids and zinc, the use of industrial oxygen, unsterilized medical equipment, frequent intubation, a weakened immune system, and pre-existing comorbidities such as diabetes. As a result, it is critical to take steps to handle the current increase in mucormycosis cases. Therefore, this article aims to highlight the existence of mucormycosis amidst the COVID-19 pandemic in India and Pakistan, focusing on possible causes and implications, and suggests important plans of action to be taken during this pandemic.

Marburg virus disease outbreak amidst COVID-19 in the Republic of Guinea: A point of contention for the fragile health system?

“…The COVID-19 pandemic caused several disruptions in many countries, which has resulted in surging cases of several infectious diseases. 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 For instance in Guinea, the pandemic increased the difficulty in accessing health services and has also negatively affected surveillance, testing, treatment for other infectious diseases. 15 , 16 The health systems were overburdened – with increased hospital workload thus influencing patient care.…”

Tuberculosis amidst COVID-19 pandemic in India: unspoken challenges and the way forward

“…The cases of TB have continuously surged in India owing to its late diagnosis and inadequate infrastructure. The advent of COVID-19 has further caused impediments in timely diagnosis of TB similar to other infectious diseases in the country [ 9 , 11 , 12 ]. As per the available data, in March 2020, the number of children receiving the Bacillus Calmette–Guérin (BCG) vaccine was 260,000 less as compared to the previous year.…”

From black to white: A roadmap to containing the rise of candidiasis amidst COVID-19 and mucormycosis in India

“… 1 , 2 , 3 On 6th May 2021, India witnessed a record-breaking peak of 414,000 new COVID-19 cases. This deadly second peak was accompanied with mucormycosis and aspergillosis infections in critically ill COVID-19 cases 4 that were linked to alarmingly increasing rates of morbidity and mortality. 5 About 71% of all documented mucormycosis case reports were reported in India, 6 with the majority observed in the states of Gujarat, Maharashtra, and Bihar.…”